Eagle Pharmaceuticals to Host Second Quarter 2022 Financial Results on August 9, 2022
July 28, 2022 16:05 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 second quarter...
Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial
July 18, 2022 06:50 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Debra M. Hussain as Senior Vice...
Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint
June 09, 2022 07:30 ET
|
Eagle Pharmaceuticals, Inc.
Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protectionBARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle...
Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker
June 01, 2022 06:50 ET
|
Eagle Pharmaceuticals, Inc.
-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter -- --...
Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock Conference
May 26, 2022 06:50 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian...
Eagle Pharmaceuticals Reports First Quarter 2022 Results
May 09, 2022 06:50 ET
|
Eagle Pharmaceuticals, Inc.
Q1 2022 net income was $3.47 per basic and $3.41 per diluted share and adjusted non-GAAP net income* was $4.10 per basic and $4.04 per diluted shareQ1 2022 total revenue was $115.9 million, up from...
Eagle Pharmaceuticals to Host First Quarter 2022 Financial Results on May 9, 2022
April 28, 2022 16:30 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first quarter...
Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028
April 19, 2022 06:50 ET
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with...
Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc
March 28, 2022 04:00 ET
|
Eagle Pharmaceuticals, Inc.
Expects to add two U.S. Food and Drug Administration (“FDA”)-approved, new chemical entities (“NCEs”) with patent life into 2031 and expand acute care footprintCommercialized assets, BARHEMSYS®...
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results
March 07, 2022 06:50 ET
|
Eagle Pharmaceuticals, Inc.
Q4 2021 net loss was $(0.48) per basic and diluted share and adjusted non-GAAP net income* was $0.87 per basic and $0.85 per diluted shareFY 2021 net loss was $(0.66) per basic and diluted share and...